Cover Image
市場調查報告書

胃泌素/膽囊收縮素B受體 (CCK-B受體或膽囊收縮素2受體或CCKBR) :開發中產品分析

Gastrin/Cholecystokinin Type B Receptor (CCK-B Receptor or Cholecystokinin-2 Receptor or CCKBR) - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 364831
出版日期 內容資訊 英文 42 Pages
訂單完成後即時交付
價格
Back to Top
胃泌素/膽囊收縮素B受體 (CCK-B受體或膽囊收縮素2受體或CCKBR) :開發中產品分析 Gastrin/Cholecystokinin Type B Receptor (CCK-B Receptor or Cholecystokinin-2 Receptor or CCKBR) - Pipeline Review, H1 2016
出版日期: 2016年06月28日 內容資訊: 英文 42 Pages
簡介

本報告提供以胃泌素/膽囊收縮素B受體 (CCK-B受體或膽囊收縮素2受體或CCKBR) 為標的之治療藥開發相關資訊,提供您開發階段,藥物標的,作用機制,給藥途徑及各分子類型分析,開發治療藥的企業概要,最新消息和新聞稿等資訊。

簡介

  • 調查範圍

胃泌素/膽囊收縮素B受體 (CCK-B受體或膽囊收縮素2受體或CCKBR)概要

治療藥的開發

胃泌素/膽囊收縮素B受體 (CCK-B受體或膽囊收縮素2受體或CCKBR):開發中的產品 - 各開發階段

胃泌素/膽囊收縮素B受體 (CCK-B受體或膽囊收縮素2受體或CCKBR):開發中的產品 - 各治療範圍

胃泌素/膽囊收縮素B受體 (CCK-B受體或膽囊收縮素2受體或CCKBR):開發中的產品 - 各適應症

胃泌素/膽囊收縮素B受體 (CCK-B受體或膽囊收縮素2受體或CCKBR):開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

胃泌素/膽囊收縮素B受體 (CCK-B受體或膽囊收縮素2受體或CCKBR):企業開發中的產品

胃泌素/膽囊收縮素B受體 (CCK-B受體或膽囊收縮素2受體或CCKBR):大學/機關開發中的產品

胃泌素/膽囊收縮素B受體 (CCK-B受體或膽囊收縮素2受體或CCKBR):治療藥的評估

  • 單劑療法/聯合治療產品別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

胃泌素/膽囊收縮素B受體 (CCK-B受體或膽囊收縮素2受體或CCKBR)治療藥的開發企業

  • Johnson & Johnson
  • Zealand Pharma A/S
  • Zeria Pharmaceutical Co., Ltd.

藥物簡介

胃泌素/膽囊收縮素B受體 (CCK-B受體或膽囊收縮素2受體或CCKBR):暫停中的計劃

胃泌素/膽囊收縮素B受體 (CCK-B受體或膽囊收縮素2受體或CCKBR):開發中止的產品

胃泌素/膽囊收縮素B受體 (CCK-B受體或膽囊收縮素2受體或CCKBR):主要消息與新聞稿

附錄

目錄
Product Code: GMDHC0022TDB

Summary

Global Markets Direct's, 'Gastrin/Cholecystokinin Type B Receptor (CCK-B Receptor or Cholecystokinin-2 Receptor or CCKBR) - Pipeline Review, H1 2016', provides in depth analysis on Gastrin/Cholecystokinin Type B Receptor (CCK-B Receptor or Cholecystokinin-2 Receptor or CCKBR) targeted pipeline therapeutics.

The report provides comprehensive information on the Gastrin/Cholecystokinin Type B Receptor (CCK-B Receptor or Cholecystokinin-2 Receptor or CCKBR), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Gastrin/Cholecystokinin Type B Receptor (CCK-B Receptor or Cholecystokinin-2 Receptor or CCKBR) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Gastrin/Cholecystokinin Type B Receptor (CCK-B Receptor or Cholecystokinin-2 Receptor or CCKBR)
  • The report reviews Gastrin/Cholecystokinin Type B Receptor (CCK-B Receptor or Cholecystokinin-2 Receptor or CCKBR) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Gastrin/Cholecystokinin Type B Receptor (CCK-B Receptor or Cholecystokinin-2 Receptor or CCKBR) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Gastrin/Cholecystokinin Type B Receptor (CCK-B Receptor or Cholecystokinin-2 Receptor or CCKBR) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Gastrin/Cholecystokinin Type B Receptor (CCK-B Receptor or Cholecystokinin-2 Receptor or CCKBR) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Gastrin/Cholecystokinin Type B Receptor (CCK-B Receptor or Cholecystokinin-2 Receptor or CCKBR)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Gastrin/Cholecystokinin Type B Receptor (CCK-B Receptor or Cholecystokinin-2 Receptor or CCKBR) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Gastrin/Cholecystokinin Type B Receptor (CCK-B Receptor or Cholecystokinin-2 Receptor or CCKBR) Overview
  • Therapeutics Development
    • Gastrin/Cholecystokinin Type B Receptor (CCK-B Receptor or Cholecystokinin-2 Receptor or CCKBR) - Products under Development by Stage of Development
    • Gastrin/Cholecystokinin Type B Receptor (CCK-B Receptor or Cholecystokinin-2 Receptor or CCKBR) - Products under Development by Therapy Area
    • Gastrin/Cholecystokinin Type B Receptor (CCK-B Receptor or Cholecystokinin-2 Receptor or CCKBR) - Products under Development by Indication
  • Gastrin/Cholecystokinin Type B Receptor (CCK-B Receptor or Cholecystokinin-2 Receptor or CCKBR) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Gastrin/Cholecystokinin Type B Receptor (CCK-B Receptor or Cholecystokinin-2 Receptor or CCKBR) - Products under Development by Companies
  • Gastrin/Cholecystokinin Type B Receptor (CCK-B Receptor or Cholecystokinin-2 Receptor or CCKBR) - Products under Development by Universities/Institutes
  • Gastrin/Cholecystokinin Type B Receptor (CCK-B Receptor or Cholecystokinin-2 Receptor or CCKBR) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Gastrin/Cholecystokinin Type B Receptor (CCK-B Receptor or Cholecystokinin-2 Receptor or CCKBR) - Companies Involved in Therapeutics Development
    • Johnson & Johnson
    • Zealand Pharma A/S
    • Zeria Pharmaceutical Co., Ltd.
  • Gastrin/Cholecystokinin Type B Receptor (CCK-B Receptor or Cholecystokinin-2 Receptor or CCKBR) - Drug Profiles
    • D-217 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JNJ-26070109 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • netazepide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Antagonize CCK-2 Receptor for Ulcer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TR-2A - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Z-360 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ZP-3022 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Gastrin/Cholecystokinin Type B Receptor (CCK-B Receptor or Cholecystokinin-2 Receptor or CCKBR) - Dormant Projects
  • Gastrin/Cholecystokinin Type B Receptor (CCK-B Receptor or Cholecystokinin-2 Receptor or CCKBR) - Discontinued Products
  • Gastrin/Cholecystokinin Type B Receptor (CCK-B Receptor or Cholecystokinin-2 Receptor or CCKBR) - Featured News & Press Releases
    • Jun 06, 2015: Presentations on ZP3022, novel Zealand preclinical peptide therapeutics as a possible approach for the treatment of Type 2 diabetes and obesity at the American Diabetes Association's (ADA) 74th Scientific Sessions
    • Sep 27, 2013: Zealand presents new preclinical data on its GLP-1-gastrin dual agonist, which shows potential as a novel approach for the treatment and/or prevention of type 2 diabetes
    • Oct 04, 2012: Zealand Pharma Presents New Preclinical Data On ZP3022 At EASD 48th Annual Meeting
    • Sep 26, 2012: Zealand Pharma To Present Preclinical Data Of ZP3022 At EASD 48th Annual Meeting
    • Jun 10, 2012: Zealand Pharma Presents Positive Preclinical Results Of ZP3022 At ADA Annual Scientific Sessions
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Indication, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Pipeline by Johnson & Johnson, H1 2016
  • Pipeline by Zealand Pharma A/S, H1 2016
  • Pipeline by Zeria Pharmaceutical Co., Ltd., H1 2016
  • Dormant Projects, H1 2016
  • Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Top 10 Indication, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
Back to Top